ESR1 and breast cancer: Although TAM and its metabolite 4-hydroxy-TAM act by antagonizing the activation of ERα (Jordan, 2003; Bekele et al., 2016), the beneficial effects of TAM in BC patients with very low, or no ERα, have also been reported (Manna and Holz, 2016).